SNSW(SH:688117) Shang Hai Zheng Quan Bao·2026-02-11 18:01Core Viewpoint - Chengdu Shengnuo Biotechnology Co., Ltd. announced its participation in the national organized procurement of pharmaceuticals, with several products expected to be selected for the new round of procurement, which is a significant step for the company in expanding its market presence and enhancing competitiveness in the peptide pharmaceutical market [1][2]. Group 1: Selected Products - The company’s subsidiary, Chengdu Shengnuo Pharmaceutical Co., Ltd., participated in the national organized procurement for the first to eighth batches, with products such as Acetate Octreotide Injection and Acetate Atosiban Injection expected to be selected [1]. - The selected products include Acetate Octreotide Injection (seventh batch), Acetate Atosiban Injection (eighth batch), Somatostatin Injection (eighth batch), Thymosin Alpha 1 Injection, and Eptifibatide Injection [1]. Group 2: Impact on the Company - The selected products are expected to enhance the company's sales revenue significantly in 2024 and the first nine months of 2025, with the procurement cycle running until the end of 2028 [2]. - The procurement will prioritize the use of selected drugs in medical institutions, ensuring the completion of the agreed procurement volume, which is expected to positively impact the company's operational development [2]. - The selection also reflects the stability and reliability of the company's drug quality, which is crucial for its competitive position in the peptide pharmaceutical market [2].